Evaluation of topical ciclosporin 0.05% for prevention of rejection in high-risk corneal grafts

British Journal of Ophthalmology

Volumn 92, Issue 10, 2008, Pages 1411-1414

  Unal M ^a,b   Yucel I ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

^b Demircikara mah 1428 3k ^*  (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; CYCLOSPORIN A; DEXAMETHASONE; METHYLPREDNISOLONE; PREDNISOLONE ACETATE;

ADULT; AGED; ARTICLE; CATARACT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA GRAFT REJECTION; CORNEA TRANSPLANTATION; DRUG EFFICACY; FEMALE; GLAUCOMA; GRAFT REJECTION; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; KAPLAN MEIER METHOD; KERATOPLASTY; LOG RANK TEST; MALE; PENETRATING KERATOPLASTY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ADULT; AGED; CORNEAL DISEASES; CORNEAL TRANSPLANTATION; CYCLOSPORINE; DEXAMETHASONE; DRUG ADMINISTRATION ROUTES; ENDOTHELIUM, CORNEAL; FEMALE; GRAFT REJECTION; GRAFT VS HOST REACTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 53649106535     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2008.143024     Document Type: Article

References (26)

1. Williams KA, Roder D, Esterman A, et al. Factors predictive of corneal graft survival. Report from the Australian Corneal Graft Registry. Ophthalmology 1992;99:403-14.
2. Maeno A, Naor J, Lee HM, et al. Three decades of corneal transplantation: indications and patient characteristics. Cornea 2000;19:7-11.
3. Randleman JB, Stulting RD. Prevention and treatment of corneal graft rejection: current practice patterns (2004). Cornea 2006;25:286-90.
4. Milani JK, Pleyer U, Dukes A, et al. Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. Ophthalmology 1993;100:890-6.
5. Bourges JL, Lallemand F, Agla E, et al. Evaluation of a topical cyclosporine A prodrug on comeal graft rejection in rats. Mol Vis 2006;12:1461-6.
6. Hid JC, The use of systemic cyclosporine A in human comeal transplantation: a preliminary report. Documenta Ophthalmol 1986;62:337-44.
7. Rumelt S, Bersudsky V, Blum-Hareuveni T. et al. Systemic cyclosporine A in high failure risk, repeated comeal transplantation. Br J Ophthalmol 2002;86:988-92.
8. Bimbaum F, Böhringer D, Sokolovska Y, et al. Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study. Transplantation 2005;79:964-8.
9. Koay PY, Lee WH, Figueiredo FC. Opinions on risk factors and management of comeal graft rejection in the United Kingdom. Cornea 2005;24:292-6.
10. Belin MW, Bouchard CS, Frantz S, et al. Topical cyclosporine in high-risk corneal transplants. Ophthalmology 1989;96:1144-50.
11. Inoue K, Amano S, Kimura C, et al. Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty. Jpn J Ophthalmol 2000;44:302-5.
12. Cosar CB, Laibson PR, Cohen EJ, et al. Topical cyclosporine in pediatric keratoplasty. Eye Contact Lens 2003;29:103-7.
13. Williams KA, Erickson SA, Coster DJ. Topical steroid, cyclosporine A, and the outcome of rat comeal allografts. Br J Ophthalmol 1987;71:239-42.
14. Bouchard CS, Cavanagh HD. The high-risk keratoplasty patient-quo vadis? Cornea 1994;13:1-3.
15. Price MO, Price FW Jr. Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes. Ophthalmology 2006;113:1785-90.
16. Perry HD, Donnenfeld ED, Acheampong A, et al. Topical Cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber. CLAO J 1998;243:159-65.
17. Parry HD, Donnenfeld ED, Kanellopoulos AJ, et al. Topical cyclosporine A in the management of postkeratoplasty glaucoma. Cornea 1997;16:284-8.
18. Tang-Liu DD, Acheampong A. Ocular pharmacokinetics and safety of ciclosporin. a novel topical treatment for dry eye. Clin Pharmacokinet 2005;44:247-61.
19. Panda A, Vanathi M, Kumar A, et al. Comeal graft rejection. Surv Ophthalmol 2007;52:375-96.
20. Hoffmann F, Wiederholt M. Lokale behandlung des homhaut transplantates beim menscheu mit cyclosporine A. Klin Monatsbl Augenheilkd 1985;187:92-6.
21. Goichot-Bonnat L, Chemla P, Pouliquen Y. Cyclosporine-A collyre dans la prevention du rejet de greffe de cornee a haut risque. J Fr Ophtalmol 1987;10:213-16.
22. Miller K, Huber C, Niederwieser D, et al. Successful engraftment of high-risk comeal allografts with short-term immunosuppression with cyclosporine. Transplantation 1988;45:651-3.
23. Bertelmann E, Reinhard T, Pleyer U. Current practice of immune prophylaxis and therapy in perforating keratoplasty: a survey of members of the Cornea Section of the German Ophthalmological Society. Ophthalmologe 2003;100:1031-5.
24. Avanduk AM, Avunduk MC, Varnell ED, et al. The comparison of efficacies of topical corticosteroids and nonsteroidal antiinflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol 2003;136:593-602.
25. Yoon KC, Heo H, Kang IS, et al. Effect of topical cyclosporin A on herpetic stromal keratitis in a mouse model. Cornea 2008;27:454-60.
26. Rao SN, Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1% with topical cyclosporine 0.05%. Am J Ophthalmol 2006;141:771-2.